Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brawn BiotechBOM:530207 +4.99%55 Piotroski F-Score is 6 as of Aug. 11, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates BOM:530207 with a GF Score™ of 55/100 and a GF Value™ of ₹20.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 977 Drug Manufacturers companies, Brawn Biotech ranks better than 78.81% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Brawn Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Brawn Biotech's Piotroski F-Score or its related term are showing as below:
BOM:530207'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 7
Current: 6
During the past 13 years, the highest Piotroski F-Score of Brawn Biotech was 7. The lowest was 3. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Brawn Biotech Piotroski F-Score Related Terms
Brawn Biotech Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Brawn Biotech's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brawn Biotech Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Brawn Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Brawn Biotech's current Net Income (TTM) was 9.4.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Brawn Biotech's return on assets of this year was 0.04590756. Brawn Biotech's return on assets of last year was -0.12325208.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Brawn Biotech's current ratio of this year was 1.12852171. Brawn Biotech's current ratio of last year was 1.87640727.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Brawn Biotech's number of shares in issue this year was 2.885. Brawn Biotech's number of shares in issue last year was 3.063.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Brawn Biotech's gross margin of this year was 0.14480171. Brawn Biotech's gross margin of last year was 0.11399183.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Brawn Biotech's asset turnover of this year was 0.82862512. Brawn Biotech's asset turnover of last year was 0.9229683.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
0
+
1
+
1
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Brawn Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Brawn Biotech (BOM:530207) has a Piotroski F-Score of 6 as of Aug. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Brawn Biotech and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Brawn Biotech's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Brawn Biotech ranks #207 out of 977 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Brawn Biotech's Piotroski F-Score too high?
Brawn Biotech's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Brawn Biotech's value of 6 is 20% above this industry median. Based on the distribution chart, Brawn Biotech ranks #207 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brawn Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brawn Biotech's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brawn Biotech ranks #207 out of 977 companies for Piotroski F-Score. This places Brawn Biotech in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Brawn Biotech's value of 6 is 20% above this benchmark. Historically, Brawn Biotech's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Brawn Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brawn Biotech's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Brawn Biotech and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brawn Biotech's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brawn Biotech stock overvalued right now?
Based on GuruFocus' analysis, Brawn Biotech (BOM:530207) is currently considered Fairly Valued. The stock's GF Value™ is ₹20.49, compared to a current price of ₹20.21 — trading 1.4% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Drug Manufacturers industry median of 5.00. Brawn Biotech's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Brawn Biotech (BOM:530207), the current Piotroski F-Score is 6 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brawn Biotech (BOM:530207) Overvalued in 2026?
Based on GuruFocus' analysis, Brawn Biotech stock appears to be undervalued.
The current stock price of ₹20.21 is trading 1.4% below its estimated GF Value™ of ₹20.49.
GuruFocus considers Brawn Biotech to be Fairly Valued.
Key valuation signals for BOM:530207:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: ₹20.49 vs. price of ₹20.21 (1.4% below fair value)
Industry Position: 20% above the Drug Manufacturers median (#207 of 977)
No single metric tells the full story. See the BOM:530207 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brawn Biotech Ltd is a healthcare company. It is engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals.
55GF Score
Get the complete analysis for BOM:530207
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530207 has been successfully added to your 
